Neuralgia Treatment Market To Reach $3.43 Billion By 2030

Neuralgia Treatment Market Growth & Trends

The global neuralgia treatment market size is expected to reach USD 3.43 billion in 2030 and is projected to grow at a CAGR of 6.7% from 2025 to 2030. The rising geriatric population, increasing incidence of trigeminal neuralgia, and the growing prevalence of diabetes are the key factors driving the market. Neuralgia is a burning, stabbing, and severe pain due to a damaged or irritated nerve.

The chronic pain in the nerves can occur due to various factors such as infection, diabetes, aging, multiple sclerosis, or any similar disorders that damage the myelin sheath protecting certain nerves. Tumor compressing the trigeminal nerve can also cause the disorder. The prevalence of chronic pain in the trigeminal nerve increases with the aging population. According to the estimates published by the WHO, the geriatric population is anticipated to rise from 900.0 million in 2015 to 2.0 billion in 2050. The geriatric population is prone to many diseases such as diabetes and trigeminal neuralgia.

As per the American Association of Neuromuscular and Electrodiagnostic Medicine, the disorder usually affects the population aged 50 years or older. It also reported that women are more prone to trigeminal neuralgia than men. As per the study, The Patient’s Journey Through Trigeminal Neuralgia published by the International Association for The Study of Pain (IASP), the incidence rate of the disorder in the general population is 3.4 to 5.9 per 100,000 population. It also reported that the incidence rate is comparatively higher in the geriatric population. Such factors are expected to boost market growth over the forecast period. Stereotactic radiosurgery and microvascular decompression are the two most common procedures being adopted to treat the disorder.

 Request a free sample copy or view report summary: Neuralgia Treatment Market Report

Neuralgia Treatment Market Report Highlights

• The surgery segment dominated the market and accounted for a share of 64.8% in 2024. The growing demand for precise, non-invasive treatment options, such as robotic radiosurgery, is a key driver for the segment

• The drug-based segment is expected to grow at the fastest CAGR of 7.0% over the forecast period

• The hospital & clinics segment accounted for the largest market revenue share in 2024. Adopting advanced, non-invasive technologies in hospitals and clinics drives the market by providing more accurate and targeted treatments

• The ambulatory surgery centers segment is expected to grow at the fastest CAGR over the forecast period

Neuralgia Treatment Market Segmentation

Grand View Research has segmented the global neuralgia treatment market report based on product, technology, and region

Neuralgia Treatment  Treatment Outlook (Revenue, USD Million, 2018 - 2030)

• Drug Based

  • Anticonvulsant Medicines

  • Tricyclic Antidepressants

• Surgery

  • Radiofrequency Thermal Lesioning

  • Stereotactic Radiosurgery

  • Microvascular Decompression

  • Others

Neuralgia Treatment End Use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital & Clinics

• Ambulatory Surgery Centers

• Others

Neuralgia Treatment Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Russia

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Neuralgia Treatment Market

• GSK plc.

• Pfizer Inc.

• Novartis AG

• Biogen

• Zydus Group (Cadila Healthcare Limited)

• H. Lundbeck A/S